Alpine Immune Sciences Inc (ALPN)

Healthcare Pharmaceuticals & Medical Research Biotechnology & Medical Research

Track Share on 𝕏

Stock chart
Ticker: ALPN Exchange: NMS


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale
Past 90 days
 
Value bought
 
Value sold
 
Net insiders buying
 
Trades (buy and sell)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Total value Details
2024-04-29 2024-04-25 S Sale

Topper James N

Non-Executive Director
19 -0.0%
64.57
1,227 USD 		19 -0.0% 64.57 1,227 USD
2024-01-29 2024-01-26 PS Planned sale

Rickey James Paul

See Remarks

Officer
44,000 -100.0%
25.00
1,100,000 USD 		44,000 -100.0% 25.00 1,100,000 USD
2024-01-29 2024-01-26 PS Planned sale

Rickey James Paul

See Remarks

Officer
73,764 -100.0%
22.31
1,645,830 USD 		73,764 -100.0% 22.31 1,645,830 USD
2024-01-29 2024-01-25 PS Planned sale

Rickey James Paul

See Remarks

Officer
236 -100.0%
22.00
5,192 USD 		236 -100.0% 22.00 5,192 USD
2023-12-29 2023-12-28 S Sale

ORBIMED ADVISORS LLC

Non-Executive Director
139,166 -34.5%
18.32
2,549,521 USD 		139,166 -34.5% 18.32 2,549,521 USD
2023-12-29 2023-12-28 S Sale

ORBIMED ADVISORS LLC

Non-Executive Director
1,195,683 -34.5%
18.32
21,904,913 USD 		1,195,683 -34.5% 18.32 21,904,913 USD
2023-12-29 2023-12-28 S Sale

ORBIMED ADVISORS LLC

Non-Executive Director
3,128 -0.8%
19.82
61,997 USD 		3,128 -0.8% 19.82 61,997 USD
2023-12-29 2023-12-28 S Sale

ORBIMED ADVISORS LLC

Non-Executive Director
26,872 -0.8%
19.82
532,603 USD 		26,872 -0.8% 19.82 532,603 USD
2023-12-29 2023-12-28 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director
1,016 -100.0%
20.04
20,362 USD 		1,016 -100.0% 20.04 20,362 USD
2023-12-29 2023-12-28 S Sale

Thompson Peter A.

Non-Executive Director
139,166 -34.5%
18.32
2,549,521 USD 		139,166 -34.5% 18.32 2,549,521 USD
2023-12-29 2023-12-28 S Sale

Thompson Peter A.

Non-Executive Director
1,195,683 -34.5%
18.32
21,904,913 USD 		1,195,683 -34.5% 18.32 21,904,913 USD
2023-12-29 2023-12-28 S Sale

Thompson Peter A.

Non-Executive Director
3,128 -0.8%
19.82
61,997 USD 		3,128 -0.8% 19.82 61,997 USD
2023-12-29 2023-12-28 S Sale

Thompson Peter A.

Non-Executive Director
26,872 -0.8%
19.82
532,603 USD 		26,872 -0.8% 19.82 532,603 USD
2023-12-29 2023-12-27 S Sale

ORBIMED ADVISORS LLC

Non-Executive Director
18,922 -4.4%
19.96
377,683 USD 		18,922 -4.4% 19.96 377,683 USD
2023-12-29 2023-12-27 S Sale

ORBIMED ADVISORS LLC

Non-Executive Director
162,576 -4.4%
19.96
3,245,017 USD 		162,576 -4.4% 19.96 3,245,017 USD
2023-12-29 2023-12-27 S Sale

Thompson Peter A.

Non-Executive Director
18,922 -4.4%
19.96
377,683 USD 		18,922 -4.4% 19.96 377,683 USD
2023-12-29 2023-12-27 S Sale

Thompson Peter A.

Non-Executive Director
162,576 -4.4%
19.96
3,245,017 USD 		162,576 -4.4% 19.96 3,245,017 USD
2023-12-27 2023-12-27 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director
29,573 -100.0%
20.04
592,717 USD 		29,573 -100.0% 20.04 592,717 USD
2023-12-27 2023-12-26 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director
24,486 -100.0%
20.22
495,217 USD 		24,486 -100.0% 20.22 495,217 USD
2023-12-27 2023-12-22 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director
37,825 -100.0%
20.43
772,595 USD 		37,825 -100.0% 20.43 772,595 USD
2023-12-21 2023-12-19 PS Planned sale

Rickey James Paul

See Remarks

Officer
15,213 -100.0%
19.21
292,222 USD 		15,213 -100.0% 19.21 292,222 USD
2023-12-21 2023-12-19 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director
2,402 -100.0%
20.01
48,064 USD 		2,402 -100.0% 20.01 48,064 USD
2023-12-18 2023-12-18 PS Planned sale

Rickey James Paul

See Remarks

Officer
1,800 -100.0%
19.00
34,203 USD 		1,800 -100.0% 19.00 34,203 USD
2023-12-18 2023-12-15 PS Planned sale

Rickey James Paul

See Remarks

Officer
45,387 -100.0%
19.09
866,383 USD 		45,387 -100.0% 19.09 866,383 USD
2023-12-18 2023-12-14 PS Planned sale

Rickey James Paul

See Remarks

Officer
11,600 -100.0%
19.00
220,406 USD 		11,600 -100.0% 19.00 220,406 USD
2023-12-12 2023-12-12 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director
8,613 -100.0%
17.32
149,138 USD 		8,613 -100.0% 17.32 149,138 USD
2023-12-12 2023-12-12 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director
32,450 -100.0%
17.32
561,888 USD 		32,450 -100.0% 17.32 561,888 USD
2023-12-12 2023-12-11 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director
68,870 -68.0%
17.26
1,189,027 USD 		68,870 -68.0% 17.26 1,189,027 USD
2023-12-12 2023-12-08 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director
8,067 -7.4%
17.08
137,784 USD 		8,067 -7.4% 17.08 137,784 USD
2023-12-06 2023-12-06 PS Planned sale

Rickey James Paul

See Remarks

Officer
6,446 -100.0%
16.08
103,650 USD 		6,446 -100.0% 16.08 103,650 USD
2023-12-06 2023-12-05 PS Planned sale

Rickey James Paul

See Remarks

Officer
418 -100.0%
16.01
6,694 USD 		418 -100.0% 16.01 6,694 USD
2023-12-06 2023-12-04 PS Planned sale

Rickey James Paul

See Remarks

Officer
63,947 -100.0%
16.06
1,026,887 USD 		63,947 -100.0% 16.06 1,026,887 USD
2023-12-01 2023-11-30 PS Planned sale

Rickey James Paul

See Remarks

Officer
700 -100.0%
16.00
11,200 USD 		700 -100.0% 16.00 11,200 USD
2023-11-14 2023-11-09 B Purchase

Decheng Capital Global Healthcare Fund (Master), LP

Large shareholder
375,000 +27.6%
12.50
4,687,500 USD 		375,000 +27.6% 12.50 4,687,500 USD
2023-11-14 2023-11-09 B Purchase

Cui Xiangmin

Non-Executive Director Large shareholder
375,000 +27.6%
12.50
4,687,500 USD 		375,000 +27.6% 12.50 4,687,500 USD
2023-11-08 2023-11-06 PS Planned sale

Rickey James Paul

See Remarks

Officer
18,003 -100.0%
16.03
288,554 USD 		18,003 -100.0% 16.03 288,554 USD
2022-02-15 2022-02-11 B Purchase

Frazier Life Sciences VIII, L.P.

Large shareholder
112,665 +8.2%
7.10
799,989 USD 		112,665 +8.2% 7.10 799,989 USD
2022-01-04 2021-12-31 S Sale

Rickey James Paul

Senior VP and CFO

Officer
17,013 -70.8%
13.92
236,756 USD 		17,013 -70.8% 13.92 236,756 USD
2021-09-17 2021-09-16 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
6,768 -4.2%
10.00
67,696 USD 		6,768 -4.2% 10.00 67,696 USD
2021-09-17 2021-09-15 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
3,484 -2.1%
10.00
34,840 USD 		3,484 -2.1% 10.00 34,840 USD
2021-06-29 2021-06-28 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
3,479 -2.1%
10.00
34,792 USD 		3,479 -2.1% 10.00 34,792 USD
2021-06-29 2021-06-25 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
9,473 -5.3%
10.01
94,865 USD 		9,473 -5.3% 10.01 94,865 USD
2021-03-08 2021-03-05 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
10,000 -3.6%
12.99
129,875 USD 		10,000 -3.6% 12.99 129,875 USD
2021-03-08 2021-03-04 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
10,000 -3.4%
13.01
130,108 USD 		10,000 -3.4% 13.01 130,108 USD
2021-02-03 2021-02-02 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
10,000 -3.3%
11.74
117,381 USD 		10,000 -3.3% 11.74 117,381 USD
2021-02-03 2021-02-01 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
7,021 -2.3%
13.20
92,698 USD 		7,021 -2.3% 13.20 92,698 USD
2021-02-03 2021-02-01 PS Planned sale

GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
2,979 -1.0%
12.07
35,968 USD 		2,979 -1.0% 12.07 35,968 USD
2020-12-30 2020-12-28 S Sale

Thompson Peter A.

Non-Executive Director Large shareholder
600,000 -16.3%
14.25
8,550,000 USD 		600,000 -16.3% 14.25 8,550,000 USD
2020-12-30 2020-12-28 S Sale

ORBIMED ADVISORS LLC

Non-Executive Director Large shareholder
600,000 -16.3%
14.25
8,550,000 USD 		600,000 -16.3% 14.25 8,550,000 USD
2020-11-23 2020-11-19 B Purchase

CONWAY ROBERT E

Non-Executive Director
10,000 +66.7%
8.03
80,300 USD 		10,000 +66.7% 8.03 80,300 USD
2019-06-03 2019-05-30 B Purchase

Rickey James Paul

Senior VP and CFO
10,000 +inf%
4.95
49,500 USD 		10,000 +inf% 4.95 49,500 USD
2019-02-12 2019-02-08 S Sale

TIGER MANAGEMENT L.L.C.

Large shareholder
25,000 -15.4%
5.85
146,245 USD 		25,000 -15.4% 5.85 146,245 USD
2019-01-23 2019-01-18 B Purchase

Thompson Peter A.

Non-Executive Director Large shareholder
372,439 +11.3%
5.37
1,999,997 USD 		372,439 +11.3% 5.37 1,999,997 USD
2019-01-23 2019-01-18 B Purchase

ORBIMED ADVISORS LLC

Non-Executive Director Large shareholder
372,439 +11.3%
5.37
1,999,997 USD 		372,439 +11.3% 5.37 1,999,997 USD
2019-01-22 2019-01-18 B Purchase

GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
190,875 +5.0%
5.37
1,024,999 USD 		190,875 +5.0% 5.37 1,024,999 USD
2019-01-22 2019-01-18 B Purchase

Topper James N

Non-Executive Director Large shareholder
372,439 +16.9%
5.37
1,999,997 USD 		372,439 +16.9% 5.37 1,999,997 USD
2019-01-22 2019-01-18 B Purchase

Venkatesan Jay

Non-Executive Director Large shareholder
190,875 +5.0%
5.37
1,024,999 USD 		190,875 +5.0% 5.37 1,024,999 USD
2019-01-22 2019-01-18 B Purchase

Alpine ImmunoSciences, L.P.

Large shareholder
190,875 +5.0%
5.37
1,024,999 USD 		190,875 +5.0% 5.37 1,024,999 USD
2019-01-22 2019-01-18 B Purchase

Frazier Life Sciences VIII, L.P.

Large shareholder
372,439 +16.9%
5.37
1,999,997 USD 		372,439 +16.9% 5.37 1,999,997 USD
2017-06-22 2017-06-20 B Purchase

BVF PARTNERS L P/IL

Large shareholder
1,715 +0.9%
2.25
3,859 USD 		1,715 +0.9% 2.25 3,859 USD
2017-06-22 2017-06-20 B Purchase

BVF PARTNERS L P/IL

Large shareholder
6,359 +0.9%
2.25
14,308 USD 		6,359 +0.9% 2.25 14,308 USD
2017-06-22 2017-06-20 B Purchase

BVF PARTNERS L P/IL

Large shareholder
9,732 +0.9%
2.25
21,897 USD 		9,732 +0.9% 2.25 21,897 USD
2017-06-07 2017-06-07 B Purchase

BVF PARTNERS L P/IL

Large shareholder
3,673 +1.9%
2.28
8,379 USD 		3,673 +1.9% 2.28 8,379 USD
2017-06-07 2017-06-07 B Purchase

BVF PARTNERS L P/IL

Large shareholder
13,046 +1.9%
2.28
29,762 USD 		13,046 +1.9% 2.28 29,762 USD
2017-06-07 2017-06-07 B Purchase

BVF PARTNERS L P/IL

Large shareholder
20,181 +1.9%
2.28
46,039 USD 		20,181 +1.9% 2.28 46,039 USD
2017-06-07 2017-06-05 B Purchase

BVF PARTNERS L P/IL

Large shareholder
3,920 +2.0%
2.29
8,979 USD 		3,920 +2.0% 2.29 8,979 USD
2017-06-07 2017-06-05 B Purchase

BVF PARTNERS L P/IL

Large shareholder
12,624 +1.8%
2.29
28,917 USD 		12,624 +1.8% 2.29 28,917 USD
2017-06-07 2017-06-05 B Purchase

BVF PARTNERS L P/IL

Large shareholder
19,206 +1.8%
2.29
43,993 USD 		19,206 +1.8% 2.29 43,993 USD
2017-06-01 2017-05-31 B Purchase

BVF PARTNERS L P/IL

Large shareholder
2,727 +1.4%
2.25
6,128 USD 		2,727 +1.4% 2.25 6,128 USD
2017-06-01 2017-05-31 B Purchase

BVF PARTNERS L P/IL

Large shareholder
10,023 +1.5%
2.25
22,522 USD 		10,023 +1.5% 2.25 22,522 USD
2017-06-01 2017-05-31 B Purchase

BVF PARTNERS L P/IL

Large shareholder
15,350 +1.5%
2.25
34,491 USD 		15,350 +1.5% 2.25 34,491 USD
2017-06-01 2017-05-30 B Purchase

BVF PARTNERS L P/IL

Large shareholder
1,805 +1.0%
2.30
4,144 USD 		1,805 +1.0% 2.30 4,144 USD
2017-06-01 2017-05-30 B Purchase

BVF PARTNERS L P/IL

Large shareholder
6,903 +1.0%
2.30
15,847 USD 		6,903 +1.0% 2.30 15,847 USD
2017-06-01 2017-05-30 B Purchase

BVF PARTNERS L P/IL

Large shareholder
10,192 +1.0%
2.30
23,398 USD 		10,192 +1.0% 2.30 23,398 USD
2017-05-19 2017-05-19 B Purchase

BVF PARTNERS L P/IL

Large shareholder
1,124 +0.6%
2.30
2,585 USD 		1,124 +0.6% 2.30 2,585 USD